Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Shares Soar on Positive OVA1, Imaging Data

NEW YORK (GenomeWeb News) – Positive data presented on Vermillion's OVA1 ovarian cancer test sent the company's stock up almost 27 percent in mid-afternoon trading today.

With less than two hours left to the trading day, Vermillion's shares were trading at $3.10 and went as high as $3.50 earlier in the day. More than 1.1 million shares traded hands, a greater-than-seven-fold increase from the three-month average daily volume of 152,623.

The spike was prompted by a presentation by the principal investigator of the multi-center OVA1 clinical trial showing that the test, when combined with imaging, achieved 98.1 percent sensitivity for all types of ovarian cancers, as well as a negative predictive value of 96.3 percent.

Fred Ueland, an associate professor of gynecology at the University of Kentucky's Markey Cancer Center, made his presentation at the 17th Annual European Society of Gynecological Oncology in Milan, Italy. He also presented data showing that a rising OVA1 score correlated with an increasing risk for ovarian malignancy.

"The current research demonstrates that OVA1 in conjunction with imaging will not only help identify more women with ovarian cancer for referral, but can give them greater confidence that their ovarian tumor is benign," Ueland said in a statement.

Vermillion's test was cleared by the US Food and Drug Administration two years ago.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.